Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Recruiting
Early Phase 1
Interventional Study
Chronic Kidney Diseases
Calciphylaxis
Calcific Uremic Arteriolopathy
Treatment
Safety
Efficacy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 9 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. 18-75 years old.
2. Clinical diagnosis of calciphylaxis, including patients with chronic kidney disease who did not or had regular dialysis (hemodialysis or peritoneal dialysis).
3. All subjects signed informed consent.
Exclusion criteria:
1. Patients who refuse to sign inf…
Contacts